Performance of ARWR Arrowhead Pharmaceuticals | -33.2% in 12m
Compare ARWR with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Arrowhead Pharmaceuticals with its related Sector/Index XBI
Performance Duell ARWR vs XBI
| TimeFrame | ARWR | XBI |
|---|---|---|
| 1 Day | -0.92% | -1.52% |
| 1 Week | 12.2% | 3.45% |
| 1 Month | 9.94% | 7.71% |
| 3 Months | -16.0% | -2.11% |
| 6 Months | -11.7% | 25.51% |
| 12 Months | -33.2% | 6.37% |
| YTD | -20.1% | 1.05% |
| Rel. Perf. 1m | -0.10 | |
| Rel. Perf. 3m | -3.18 | |
| Rel. Perf. 6m | -3.58 | |
| Rel. Perf. 12m | -4.84 |
Is Arrowhead Pharmaceuticals a good stock to buy?
No, based on ValueRay Fundamental Analyses, Arrowhead Pharmaceuticals (NASDAQ:ARWR) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -85.03 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARWR as of May 2024 is 21.30. This means that ARWR is currently overvalued and has a potential downside of -14.01% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARWR as of May 2024 is 21.30. This means that ARWR is currently overvalued and has a potential downside of -14.01% (Sold with Premium).
Is ARWR a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 4
- Sell: 0
- Strong Sell: 0
Values above 0%: ARWR is performing better - Values below 0%: ARWR is underperforming
Compare ARWR with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 10.53% | 4.17% | -30.01% | -62.58% |
| US NASDAQ 100 | QQQ | 9.99% | 3.85% | -29.19% | -70.58% |
| US Dow Jones Industrial 30 | DIA | 10.82% | 3.77% | -27.19% | -55.25% |
| German DAX 40 | DBXD | 12.58% | 4.97% | -28.71% | -50.00% |
| UK FTSE 100 | ISFU | 10.68% | 0.14% | -28.58% | -48.60% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 11.07% | 5.42% | -15.05% | -25.56% |
| Hongkong Hang Seng | HSI | 8.45% | -13.34% | -16.76% | -27.87% |
| Japan Nikkei 225 | EXX7 | 11.81% | 10.44% | -23.21% | -45.04% |
| India NIFTY 50 | INDA | 9.07% | 6.02% | -29.30% | -61.95% |
| Brasil Bovespa | EWZ | 11.74% | 4.70% | -9.89% | -45.56% |
ARWR Arrowhead Pharmaceuticals vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 11.18% | 6.63% | -30.23% | -70.71% |
| Consumer Discretionary | XLY | 11.84% | 6.24% | -19.06% | -52.90% |
| Consumer Staples | XLP | 11.42% | 3.36% | -25.96% | -38.81% |
| Energy | XLE | 10.98% | 9.06% | -25.84% | -58.45% |
| Financial | XLF | 10.60% | 2.89% | -34.14% | -66.30% |
| Health Care | XLV | 10.29% | 4.26% | -26.73% | -46.73% |
| Industrial | XLI | 12.46% | 6.46% | -31.41% | -61.56% |
| Materials | XLB | 11.84% | 6.40% | -27.74% | -53.85% |
| Real Estate | XLRE | 9.67% | 1.46% | -21.36% | -43.21% |
| Technology | XLK | 9.12% | 3.42% | -28.04% | -71.54% |
| Utilities | XLU | 10.68% | -2.95% | -29.92% | -45.91% |
| Aerospace & Defense | XAR | 11.41% | 1.48% | -27.26% | -57.38% |
| Biotech | XBI | 8.73% | 2.23% | -37.23% | -39.60% |
| Homebuilder | XHB | 12.50% | 3.60% | -42.23% | -84.08% |
| Retail | XRT | 10.10% | 2.48% | -32.56% | -58.42% |
Does Arrowhead Pharmaceuticals outperform its market, is ARWR a Sector Leader?
No, over the last 12 months Arrowhead Pharmaceuticals (ARWR) made -33.23%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.37%.
Over the last 3 months ARWR made -15.98%, while XBI made -2.11%.
No, over the last 12 months Arrowhead Pharmaceuticals (ARWR) made -33.23%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.37%.
Over the last 3 months ARWR made -15.98%, while XBI made -2.11%.
| Period | ARWR | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 9.94% | 7.71% | 5.77% |
| 3 Months | -15.98% | -2.11% | 6.32% |
| 12 Months | -33.23% | 6.37% | 29.35% |